Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Cardiovasc Drugs Ther ; 24(1): 33-40, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20229056

ABSTRACT

OBJECTIVE: To compare the effects of an angiotensin receptor blocker(ARB)-based regimen versus a non-ARB based regimen on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction. METHODS: 97 patients with a systolic blood pressure (SBP) > or =140 mmHg, a left ventricular ejection fraction >0.50, and echocardiographic evidence of diastolic dysfunction were randomly assignment to open-label treatment with eprosartan (with other anti-hypertensives; n = 47) or other anti-hypertensives alone (n = 50). Echocardiography, including tissue Doppler imaging (TDI), and neurohormones were done at baseline and after 6 months. RESULTS: Mean age was 65 (+/-10) years and 64% was female. During 6 months of treatment, SBP decreased from 157 +/- 16 to 145 +/- 18 mmHg in the eprosartan group and from 158 +/- 17 to 141 +/- 18 mmHg in the control group (both p < 0.001; p = ns between groups). Diastolic function was unaffected in both groups and there was no correlation between changes in SBP and changes in mean TDI (r = -0.06; p = 0.58). Aldosterone levels decreased in the eprosartan group, but other neurohormones remained largely unchanged. Change in SBP was however related to the change in NT-proBNP (r = 0.26; p = 0.019). CONCLUSION: Lowering blood pressure, either with eprosartan or other anti-hypertensives in hypertensive patients with diastolic dysfunction did not change diastolic function after 6 months of treatment, but was associated with a decrease of NT-proBNP.


Subject(s)
Acrylates/therapeutic use , Diastole/drug effects , Hypertension/drug therapy , Imidazoles/therapeutic use , Neurotransmitter Agents/blood , Thiophenes/therapeutic use , Ventricular Dysfunction/drug therapy , Ventricular Function/drug effects , Acrylates/adverse effects , Acrylates/pharmacology , Aged , Aldosterone/blood , Angiotensin II Type 1 Receptor Blockers/adverse effects , Angiotensin II Type 1 Receptor Blockers/pharmacology , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Antihypertensive Agents/adverse effects , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Blood Pressure/physiology , Diastole/physiology , Echocardiography , Female , Heart/drug effects , Heart/physiopathology , Humans , Hypertension/blood , Hypertension/complications , Imidazoles/adverse effects , Imidazoles/pharmacology , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Peptidyl-Dipeptidase A/blood , Stroke Volume/drug effects , Stroke Volume/physiology , Thiophenes/adverse effects , Thiophenes/pharmacology , Treatment Outcome , Ventricular Dysfunction/blood , Ventricular Dysfunction/complications , Ventricular Dysfunction/physiopathology , Ventricular Function/physiology , Ventricular Function, Left/drug effects , Ventricular Function, Left/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...